Rituximab Therapy for Steroid-dependent Minimal Change Nephrotic Syndrome

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2006 Aug 26

PMID 16932900

Citations 48

Authors

Rodney D Gilbert

Eleanor Hulse

Susan Rigden

Affiliations

Soon will be listed here.

Abstract

We present a patient with steroid-sensitive but high-dose steroid-dependent nephrotic syndrome who was treated with rituximab. For 9 months following therapy she had undetectable CD19 cells in the peripheral circulation. She remained in remission during this period even though therapy was reduced to low-dose, alternate day prednisolone only. After 9 months, CD19 cells were once again detectable. Shortly after CD19 cells became detectable again she relapsed. We conclude that B-lymphocytes play a central role in the pathogenesis of idiopathic minimal change nephrotic syndrome (MCNS) and that rituximab may have a useful role in the management of steroid-dependent patients.

Citing Articles

Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study.

Chen Y, Shen Q, Xiong Y, Dong M, Xu H, Li Z Front Pharmacol. 2024; 14:1319744.

PMID: 38264525 PMC: 10803641. DOI: 10.3389/fphar.2023.1319744.

"Idiopathic" minimal change nephrotic syndrome: a podocyte mystery nears the end.

Chugh S, Clement L Am J Physiol Renal Physiol. 2023; 325(6):F685-F694.

PMID: 37795536 PMC: 10878723. DOI: 10.1152/ajprenal.00219.2023.

Prognostic factors of severe pneumonia in patients treated with rituximab in the intensive care unit.

Yao L, Huang Y, Xu A J Int Med Res. 2022; 50(3):3000605211063281.

PMID: 35350908 PMC: 8973072. DOI: 10.1177/03000605211063281.

Rituximab Use in the Management of Childhood Nephrotic Syndrome.

Kallash M, Smoyer W, Mahan J Front Pediatr. 2019; 7:178.

PMID: 31134169 PMC: 6524616. DOI: 10.3389/fped.2019.00178.

Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients.

Colliou E, Karras A, Boffa J, Ribes D, Garrouste C, le Quintrec M J Clin Med. 2019; 8(3).

PMID: 30832362 PMC: 6463053. DOI: 10.3390/jcm8030298.

References

Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M . Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol. 2005; 20(11):1660-3. DOI: 10.1007/s00467-005-2013-7. View

Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux M, Landais P . Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis. 2003; 41(3):550-7. DOI: 10.1053/ajkd.2003.50116. View

Benz K, Dotsch J, Rascher W, Stachel D . Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004; 19(7):794-7. DOI: 10.1007/s00467-004-1434-z. View

van den Berg J, Weening J . Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci (Lond). 2004; 107(2):125-36. DOI: 10.1042/CS20040095. View

Meyrier A . Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol. 2006; 1(1):44-54. DOI: 10.1038/ncpneph0025. View

Garin E, Laflam P, Chandler L . Anti-interleukin 8 antibody abolishes effects of lipoid nephrosis cytokine. Pediatr Nephrol. 1998; 12(5):381-5. DOI: 10.1007/s004670050470. View

Kemper M, Meyer-Jark T, Lilova M, Muller-Wiefel D . Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol. 2003; 60(4):242-7. DOI: 10.5414/cnp60242. View

Marks S, Tullus K . Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol. 2006; 21(4):598-9. DOI: 10.1007/s00467-006-0024-7. View

Mansour H, Cheval L, Elalouf J, Aude J, Alyanakian M, Mougenot B . T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome. Kidney Int. 2005; 67(6):2168-77. DOI: 10.1111/j.1523-1755.2005.00322.x. View

10.

Grimbert P, Audard V, Valanciute A, Pawlak A, Lang P, Guellaen G . Abnormal RNA processing and altered expression of serin-rich proteins in minimal-change nephrotic syndrome. Pediatr Res. 2004; 57(1):133-7. DOI: 10.1203/01.PDR.0000148013.53429.5B. View

11.

Tarshish P, Tobin J, Bernstein J, EDELMANN Jr C . Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997; 8(5):769-76. DOI: 10.1681/ASN.V85769. View

12.

Niemir Z, Stein H, Ciechanowicz A, Olejniczak P, Dworacki G, Ritz E . The in situ expression of interleukin-8 in the normal human kidney and in different morphological forms of glomerulonephritis. Am J Kidney Dis. 2004; 43(6):983-98. DOI: 10.1053/j.ajkd.2004.02.011. View

13.

KOSKIMIES O, VILSKA J, Rapola J, HALLMAN N . Long-term outcome of primary nephrotic syndrome. Arch Dis Child. 1982; 57(7):544-8. PMC: 1627702. DOI: 10.1136/adc.57.7.544. View

14.

Kemper M, Zepf K, Klaassen I, Link A, Muller-Wiefel D . Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse. Am J Nephrol. 2005; 25(2):132-7. DOI: 10.1159/000085357. View

15.

Ruth E, Kemper M, Leumann E, Laube G, Neuhaus T . Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. 2005; 147(2):202-7. DOI: 10.1016/j.jpeds.2005.03.050. View

16.

Hodson E, Craig J, Willis N . Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2005; 20(11):1523-30. DOI: 10.1007/s00467-005-1968-8. View